Open access

675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC)
A Dimitrios Colevas, Katie Kerrigan, Venessa Chin, Natalie Rainey, John Park, Bruno Fang, Diogo Alpuim Costa, José Dinis, Minh Phan, Lanjia Lin, Yiran Zhang, Siu-Chi Chang Sun, Michael Howland, Kelly Curtis, Douglas Adkins

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A765-A766; DOI: 10.1136/jitc-2023-SITC2023.0675
676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)
Terrence Fisher, Elizabeth Evans, Crystal Mallow, Amber Foster, John Leonard, Marya Chaney, Tarek Mekhail, Nagashree Seetharamu, Conor Steuer, Nabil F Saba, Douglas Adkins, J Thaddeus Beck, Alain Algazi, Barbara Burtness, Megan Baumgart, Steven Hager, Christopher Chay, Alexander Spira, Maurice Zauderer

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A767; DOI: 10.1136/jitc-2023-SITC2023.0676
677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer
Michael K Gibson, Panayiotis Savvides, Francis Worden, Ellen Heimann-Nichols, TC Wu, Richard Roden, Yung-Nien Chang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A768; DOI: 10.1136/jitc-2023-SITC2023.0677
678 Updated safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): a phase Ib/II clinical trial
Ye Guo, Zhendong Li, Desheng Hu, Song Qu, Youhua Zhu, Meiyu Fang, Wantao Chen, Chuanzheng Sun, Hao Jiang, Jingfeng Zong, Jinguan Lin, Siyang Wang, Wei Wang, Chuan Jin, Guochun Cao, Minghua Ge, Xiaoming Huang, Xudong Wang, Zhiming Li, Mo Wang, Xianming Luo, Shuanghui Wei, Yuteng Shen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A769; DOI: 10.1136/jitc-2023-SITC2023.0678
679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study
Alan L Ho, Alexander T Pearson, Siqing Fu, Marshall R Posner, Douglas Adkins, Lisle Nabell, Jiaxin Niu, Debra L Richardson, Rom S Leidner, Ki Chung, Douglas Laux, Jorge Nieva, Stuart Wong, Katerin Rojas, Ari J Rosenberg, Minh Phan, Trisha Kaufmann, Christopher Plescia, Xiaoping Qing, Corinne Iacobucci, Ilian Tchakov, Kia Katchar, Klaus Orlinger, Katia Schlienger, David G Pfister

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A770; DOI: 10.1136/jitc-2023-SITC2023.0679
680 Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma
Christopher Paustian, Tarsem Moudgil, Venkatesh Rajamanickam, Noah Simons, Ryan Meng, Marcus Couey, Matthew H Taylor, Yoshinobu Koguchi, Annie Stadum, Tanisha Christie, Tyler Hulett, Noriko Iwamoto, Takashi Shimada, Yuriko Minegishi, Quyen Vu, William L Redmond, Lessli Rushforth, Abigail Peterson, Brady Bernard, R Bryan Bell, Carlo Bifulco, Koji Ueda, Traci Hilton, Shawn M Jensen, Hong-Ming Hu, Brian Piening, Walter J Urba, Bernard A Fox, Rom S Leidner

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A771; DOI: 10.1136/jitc-2023-SITC2023.0680
681 innovaTV 207 Parts E and F: a phase 2 study of tisotumab vedotin in patients with head and neck squamous cell carcinoma (trial in progress)
Tanguy Y Seiwert, Lara A Dunn, Lova Sun, Thomas J George, Dan P Zandberg, Christine H Chung, William N William, Douglas Adkins, Kristi Schmidt, Ibrahima Soumaoro, Leonardo Nicacio, Nabil F Saba

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A772-A773; DOI: 10.1136/jitc-2023-SITC2023.0681
682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation
Monzr Al Malki, Alla Keyzner, Hyung C Suh, Aasiya Matin, Erica Buonomo, Yun Wang, Nina Abelowitz, Jim Murray, Gavin MacBeath, Debora Barton, Shrikanta Chattopadhyay, Ran Reshef

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A774; DOI: 10.1136/jitc-2023-SITC2023.0682
683 Phase I first-in-human study on the feasibility, safety, and antitumor activity of CD4-redirected chimeric antigen receptor (CAR) T-cell therapy in patients with CD4+ T-cell malignancies (TCM)
Rita Assi, Nabil Hagag, Sherif Farag, Robert Emmons, Allie Carter, Magdalena Czader, Rafat Abonnour, Lionel Apetoh, Yupo Ma, Huda Salman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A775-A776; DOI: 10.1136/jitc-2023-SITC2023.0683
684 Assay development and quantitative detection of ADI-001, a CD20-targeted γδ1 CAR T therapy, using AlloCell, a universal assay for monitoring of off-the-shelf allogeneic cell therapies
Jackie Kennedy-Wilde, Lilly Wong, Monica Moreno, Collin DuBois, David Liu, Divya Kilam, Natali Gulbahce, Andrew Wrong, Monika Maleszewska, Yining Yi, Francesco Galimi, Rose Lai, Blake T Aftab

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A777; DOI: 10.1136/jitc-2023-SITC2023.0684

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages